Literature DB >> 20809015

Prostate lesions with cribriform / pseudocribriform pattern.

Alis Dema1, Angela Borda, Elena Lazăr, Codruţa Lăzureanu, Sorina Tăban, Denisa Anderco, Mărioara Cornianu, Anca Mureşan, Diana Herman, Andrada Loghin, R Cornea, Alexandra Faur.   

Abstract

Prostate lesions with cribriform / pseudocribriform architecture range from normal histological structures to infiltrative carcinoma. In each group of lesions with cribriform architecture (benign, premalignant and malignant intraductal or infiltrating), there are situations in which histological classification of the lesion is difficult or impossible on routine stains. A more wide-scale application of the immunohistochemical investigation for clearing up the problematic prostate lesions led to the definition and reclassification of cribriform lesions in distinct categories and sometimes very different in terms of progression, prognosis and treatment. This paper proposes an overview of the prostate lesions with cribriform / pseudocribriform architecture, emphasizing the morpho-immunohistochemical criteria for positive and differential diagnosis.

Entities:  

Mesh:

Year:  2010        PMID: 20809015

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  2 in total

1.  NRIP/DCAF6 stabilizes the androgen receptor protein by displacing DDB2 from the CUL4A-DDB1 E3 ligase complex in prostate cancer.

Authors:  Hsin-Hsiung Chen; Ping Fan; Szu-Wei Chang; Yeou-Ping Tsao; Hsiang-Po Huang; Show-Li Chen
Journal:  Oncotarget       Date:  2017-03-28

2.  Prolactin promotes a partial recovery from the atrophy of both male and female gerbil prostates caused by castration.

Authors:  Marianna Zanatelli; Simone Jacovaci Colleta; Luiz Henrique Alves Guerra; Fernanda Cristina Alcântara Santos; Rejane Maira Góes; Patricia Simone Leite Vilamaior; Sebastião Roberto Taboga
Journal:  Reprod Biol Endocrinol       Date:  2021-06-22       Impact factor: 5.211

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.